Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Pharma to Receive 100 Million Doses of COVID-19 Vaccine for China Use

publication date: Dec 16, 2020
 | 
author/source: Richard Daverman, PhD

Shanghai Fosun Pharma (SHA: 600196; HK: 02196) announced its German partner, BioNTech (NSDQ: BNTX), will supply 100 million doses of their partnered COVID-19 vaccine for China use. In March, Fosun in-licensed China rights to the vaccine in a $135 million deal that included a $50 million Fosun investment in BioNTech. The two companies started a China Phase II bridging study of the vaccine one month ago that enrolled 960 healthy volunteers. The BioNTech-discovered mRNA vaccine is already launched in the US (partnered with Pfizer) and Britain.

Fosun said the China trial is progressing on schedule. In other countries, the vaccine is being administered in two doses, 21 days apart, and then evaluated two months after the second dose.

The two companies said China's regulators have advanced the candidate quickly in a model of how international cooperation for important medications should take place. Fosun added that its plans for commercializing the vaccine are already being formed.

“We would like to thank the Chinese government and National Medical Products Administration for their commitment and trust in our vaccine development efforts to help address this global pandemic threat,” said Ugur Sahin, MD, CEO and Co-founder of BioNTech. “This joint development effort with Fosun Pharma is a testament to the importance of global cooperation and reflects our strategy to supply our vaccine globally.”

“Since the outbreak of the COVID-19 epidemic, we have been working closely with BioNTech. With the support of the Joint Prevention and Control Mechanism of the State Council, especially the National Medical Products Administration, the National Health Commission, the Ministry of Science and Technology and other relevant authorities, the R&D and clinical trial of our COVID-19 mRNA vaccine in China has been moved forward rapidly. On the premise of ensuring the safety and effectiveness of the vaccine, we actively support the marketing of the vaccine in China,” Yifang Wu, Chairman and CEO of Fosun Pharma said. “

See our other articles on Fosun and BioNTech.

Disclosure: none.

 

 

 

 


 

Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital